Chelators, iron anemia, design

The choice of iron chelators on the basis of both molecular and cellular criteria was discussed in 2003 (374). One 2005 review is concerned with the design of orally active iron chelators (375), another considers the prospects for effective clinical use of several hydro-x5rpyridinones, dealing with novel species such as the 1-allyl compound as well as with the established deferiprone (LI) and desferrioxamine (Desferal, DFO) (376). A review dated 2006 deals with relevance of iron mobilization from both transferrin and other iron-containing proteins by LI to the treatment of various anemias and other iron-overload conditions (377). Two 2007 reviews concentrate on LI, as the only hydroxypyridinone in general clinical use. One author concludes that, on balance, LI is to be preferred to DFO. This conclusion is on the grounds that, despite the not infrequent occurrence of minor side effects, the incidence of serious side effects... 

Design of Polymeric Iron Chelators for Treating Iron Overload in Cooley s Anemia... 

Cooley s anemia (P-thalassemia major), with chronic transfusional iron overload, probably best illustrates the hurdles which must be overcome in chelator design. The lifelong treatment necessary in this disorder dictates that both the long-term toxicity of the drug and the efficiency wiA which the ligand... 

---